Skip to main content

Select Drug Profiles

FDA Approvals, Urothelial Cancer, Conference Highlights ASCO, Oncology

Padcev Receives Regular FDA Approval for Locally Advanced or Metastatic Urothelial Cancer

Melanoma, Conference Highlights ASCO, Oncology

Novel LAG-3–Blocking Antibody plus Nivolumab Shows Promise as First-Line Treatment in Advanced Melanoma

Wayne Kuznar

Prostate Cancer, Conference Highlights ASCO

¹⁷⁷Lu-PSMA-617 Prolongs Survival in Patients with Metastatic Castration-Resistant Prostate Cancer

Phoebe Starr

Conference Highlights ASCO

Early Phase 3 Results Show Survival Benefit with Nivolumab-Based Regimens in Advanced Esophageal Squamous-Cell Cancer

Wayne Kuznar

Renal-Cell Carcinoma, Conference Highlights ASCO, Oncology

Adjuvant Pembrolizumab Therapy Significantly Extends Disease-Free Survival in Patients with Clear-Cell Renal-Cell Carcinoma

Phoebe Starr

Opdivo First FDA-Approved Immunotherapy for First-Line Treatment of Advanced Gastric Cancer

Keytruda Received FDA Approval for First-Line Treatment of HER2-Positive Advanced Gastric Cancer

Trodelvy Receives New Indication for Advanced Urothelial Cancer

Sarclisa Receives New Indication for Relapsed or Refractory Multiple Myeloma

FDA Alert: Pepaxto (Melphalan Flufenamide) Associated with Increased Risk of Death in Postmarketing Clinical Trial

Page 21 of 244
Results 201 - 210 of 2434